Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000010

Drug Information
NameCYC116
CompanyCyclacel Limited
IndicationSolid Tumors
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Terminated in Phase I    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C18H20N6OS/c1-12-16(26-17(19)21-12)15-6-7-20-18(23-15)22-13-2-
4-14(5-3-13)24-8-10-25-11-9-24/h2-7H,8-11H2,1H3,(H2,19,21)(H,20,2
2,23)
InChIKeyGPSZYOIFQZPWEJ-UHFFFAOYSA-N
Canonical SMILESCC1=C(SC(=N1)N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4CCOCC4    
Therapeutic ClassAntineoplastic Agents
PubChem Compound IDCID 6420138.
ClinicalTrials.govNCT00530465;
TargetAurora-AInhibitor[1]
Aurora-AMultitarget[1]
Aurora-BInhibitor[1]
Aurora-BMultitarget[1]
Vascular endothelial growth factor receptor 2Inhibitor[1]
Vascular endothelial growth factor receptor 2Multitarget[1]
Ref 1Report from Cyclacel Pharmaceuticals. Cyclacel Limited. April 2008 To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543